Genmedica Therapeutics
Silvia García, Project Manager
Address: Joan XXIII, 10
City: Esplugues de Llobregat
Province: Barcelona
Phone: 34 93 230 12 98
Mission and Objectives
Genmedica Therapeutics is a clinical-stage biopharmaceutical company focused on the research and development of new treatments in the field of diabetes. Our headquarters are located in the Ferrer Science Park. Genmedica has developed a novel NCE-generating platform to generate dual action, small molecules that act against oxidative stress and inflammation, two specific pathways known to be critical in the root causes of the disease.
Products/Services, Areas of interest for future collaborations/Alliances
GMC-252 is the company’s most advanced compound. It is a novel oral therapy for the treatment of type 2 diabetes. It works by targeting oxidative stress and inflammation via its dual moieties (GMC-252 is a single small molecule constructed from a known anti-inflammatory (NSAID) and a known anti-oxidant compound). A Phase 1A clinical trial in healthy volunteers has been completed, and A Phase 1B/2A clinical study in diabetic patients has been planned as the next step in the development of GMC-252.

Genmedica Therapeutics
Developed by Web4Bio